Therapy of cardioneurosis with modern antidepressants in general medical care network
https://doi.org/10.33667/2078-5631-2021-25-26-32
Abstract
The clinical presentation of cardioneurosis is heterogeneous and includes anxiety-phobic, cenestalgic, and depressive symptoms. General practitioners, who most often see this category of patients, usually recommend to take «sedatives». Modern antidepressant, i. e. selective serotonin reuptake inhibitor, escitalopram demonstrated high efficiency and good tolerability in patients with cardoneurosis (neurocirculatory dystonia).
About the Authors
V. E. Medvedev
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Medvedev V. E., PhD Med, associate professor, head of Dept of Psychiatry, Psychotherapy and Psychosomatic Pathology, Faculty of Continuing Medical Education of Medical Institute
Moscow
V. I. Frolova
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Frolova V. I., PhD Med, associate professor at Dept of Psychiatry, Psychotherapy and Psychosomatic Pathology, Faculty of Continuing Medical Education of Medical Institute
Moscow
O. V. Kotova
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Kotova O. V., PhD Med, associate professor at Dept of Psychiatry, Psychotherapy and Psychosomatic Pathology, Faculty of Continuing Medical Education of Medical Institute
Moscow
References
1. Bach M., Nutzinger D. O., Hart L. Comorbidity of anxiety disorders and hypochondriasis considering different diagnostic systems. Compr. Psychiat. 1996; V. 37.
2. Barsky A. J. Amplification, somatization, and the somatoform disorders. Psychosomatics. 1992; V. 33.
3. Conti S., Savron G., Bartolucci G., et al. Cardiac neurosis and psychopathology. Psychother. Psychosom. 1989; V. 52: 88–91.
4. Fava G. A., Magelli C., Savron G., et al. Neurocirculatory asthenia. A reassessment using modern psychosomatic criteria. Acta Psychiatr Scand. 1994; 89: 314–9.
5. Fink P. The prevalence of somatoform disorders among internal medical inpatients. Journal of Psychosomatic Research. 2004; 56: 413–418.
6. Kores Plesničar B. Epidemiologija, etiologija, klinična slika in diagnostika depresije. Farm Vest. 2006; 57 (4): 241–244.
7. Vein A. M., Voznesenskaya T. G., Vorob’eva O. V. Vegetative disorders. Clinic, diagnostics, treatment. Edited by A. M. Vein. MIA., 2000.
8. Dovzhenko T. V. Disorders of the depressive spectrum with cardialgic syndrome in patients with cardiovascular diseases (clinical picture, diagnostics, therapy). Diss … doct. med. sciences. M., 2008.
9. Ivanov S. V. Somatoform disorders (organ neuroses): epidemiology, comorbid psychosomatic relationships, therapy: Dis. doct. medical sciences. M., 2002.
10. Maychuk E. Yu., Dovzhenko T. V. Peculiarities of pain perception in cardialgia of organic and functional origin and methods of their correction. Pain magazine. 2003; 1: 26–30.
11. Makolkin V. I., Abbakumov S. A., Sapozhnikova A. A. Cardiopsychoneuros. Cheboksary, 1995; 248.
12. Marincheva L. P., Zlokazova M. V., Soloviev A. G. Socio-psychological and clinical risk factors for the formation of somatoform autonomic dysfunction of the cardiovascular system in adolescents. Review of Psychiatry and Medical Psychology. 2008; 1: 20–23.
13. V. E. Medvedev et al. Psychopathological and pathocharacterological characteristics of patients with cardioneurosis (neurocirculatory dystonia). Mental disorders in general medicine. 2008; 2: 18–21.
14. V. E. Medvedev Mexidol in psychiatric practice. Psychiatry and psychopharmacotherapy. 2010; 4: 18–21.
15. V. E. Medvedev. Nootropic drugs and neuroprotective agents in the treatment of mental disorders (textbook). M., 2015; 152 p.
16. V. E. Medvedev. Problems of therapy for disorders of the anxiety-depressive continuum. Psychiatry and psychopharmacotherapy. 2014; 4: 58–60.
17. Medvedev V. E., Albantova K. A. Pantogam-active in the treatment of neurotic, stress-related and somatoform disorders in cardiological patients. Mental disorders in general medicine. 2009; 2: 40–43.
18. Medvedev V. E., Epifanov A. V. Therapy of neurotic, stress-related and somatoform disorders in patients with essential hypertension with Pantogam active. Russian Psychiatric Journal. 2011: 1; 55–61.
19. Gromov L. A., Chaika L. A., Gomon O. N., Merkulova Yu. V. Selective serotonin reuptake inhibitors: current status in the treatment of depression. Rational pharmacotherapy. 2008; 3.
20. V. E. Medvedev. Depressive disorders. Chapter in the manual. Guide to medical appointments. A modern guide for medical practitioners. Volume 6. Edited by A. I. Martynov. M .: Bionika Media, 2018. (272 p.); 57–69.
21. V. E. Medvedev Differentiated approach to depression therapy. Mental health. 2015; 3: 45–53.
22. V. E. Medvedev et al. Cardioneurosis (“Neurocirculatory dystonia”). Experience of using the drug Oprah. Review of Psychiatry and Med. psychology them. Ankylosing spondylitis. 2008; 4: 35–40.
23. V. E. Medvedev Effectiveness and tolerability of modern antidepressants: results of network meta-analyzes and Russian experience. Journal of Neurology and Psychiatry. S. S. Korsakov. 2018; 118 (11): 109–117.
24. Medvedev V. E., Epifanov A. V. An innovative method of treating depression in patients with coronary heart disease. Review of Psychiatry and Medical Psychology named after V. M. Ankylosing spondylitis. 2010; 3: 31–36.
25. Medvedev V. E., Kardashian R. A., Frolova V. I., Burno A. M., Nekrasova S. V., Salyntsev I. V. Investigation of the effectiveness of various antidepressant replacement regimens in the development of SSRI-induced apathy. Neurology, neuropsychiatry and psychosomatics. 2020: 2; 48–56.
26. Medvedev V. E., Korovyakova E. A., Frolova V. I., Gushanskaya E. V. Antidepressant therapy in patients with cardiovascular diseases. Neurology, neuropsychiatry and psychosomatics. 2019; 11 (1): 131–140.
27. Medvedev V. E., Ter-Israelyan A. Yu., Frolova V. I., Gushanskaya E. V., Burno A. M., Nekrasova S. V., Salyntsev I. V., Zuikova N. L. Optimization of therapy for mental disorders with a multisyndromic clinical picture. Psychiatry and psychopharmacotherapy. 2020: 1; 23–27.
28. Medvedev V. E., Frolova V. I., Ter-Israelyan A. Yu., Korovyakova E. A., Gushanskaya E. V. Therapy of depressive disorders occurring with circanual rhythms. Psychiatry and psychopharmacotherapy. 2018; 20 (5): 38–43.
29. Bandelow B., Andersen H. F., Dolberg O. T. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress. Anxiety. 2006.
30. Cipriani A., Furukawa T. A., Salanti G., et al. Сравнение эффективности и пере- носимости 12 антидепрессантов нового поколения: результаты метаанализа (расширенный реферат). Психиатрия и психофармакотерапия. 2009; 2. Cipriani A., Furukawa T. A., Salanti G., et al. Comparison of the efficacy and tolerability of 12 new generation antidepressants: results of a meta-analysis (extended abstract). Psychiatry and psychopharmacotherapy. 2009; 2.
31. Davidson Jr., Bose A., Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry. 2005; 66 (11): 1441–1446.
32. Dhillon S., Scott L. J., Ploster G. L. Escitalopram. An overview of the use of the drug in the treatment of anxiety disorders (part I). Psychiatry and psychopharmacotherapy. 2007; 3.
33. Lepola U. M., Loft H., Reines E. H. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care Int Clin Psychopharmacol. 2003; 18: 211–217.
34. Llorca P. M., Azorin J. M., Despiegel N., Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int.J.Clin.Pract. 2005; 59 (3): 268–275.
35. Rapaport M. H., Bose A., Zeng H. Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes. J Clin Psychiat. 2004; 65: 44–49.
36. Stahl S. M., Gergel I., Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2003; 64 (11): 1322–1327.
37. Stein D. J., Andersen H. F., Goodman W. K. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann. Clin. Psychiatry. 2005; 17 (2): 71–75.
38. Stein D. J., Kasper S., Andersen E. W., et al. Escitalopram in the treatment of social anxiety disorder. Depression and Anxiety 2004. 20: 175–181.
39. Wade A., Lemming O. M., Bang Hedegaard K. Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2002; 17: 95–102.
40. Abramova L. I., Oleichik I. V., Ivanets N. N., et al. Cipralex (escitalopram) in the treatment of severe endogenous depression: features of therapeutic efficacy and tolerability. Psychiatry and psychopharmacotherapy. 2007; 2.
41. Drobizhev M. Yu., Ivanov S. V. Escitalopram is a representative of a new generation of selective serotonin reuptake inhibitors. Social and Clinical Psychiatry. 2005; 3: 81–87.
42. V. E. Medvedev. Lenuxin in the treatment of depression. Psychiatry and psychopharmacotherapy. 2012; 4: 42–45.
43. V. E. Medvedev Post-marketing study of the safety and efficacy of Elycea (escitalopram) in the treatment of depressive and anxiety disorders (abstract). Psychiatry and psychopharmacotherapy. 2013; 4: 65–68.
44. Medvedev V. E., Zuikova N. L. Prospects for the use of escitalopram (Selectra) in the treatment of depression and anxiety disorders in patients of the general medical network. Review of Psychiatry and Medical Psychology named after V. M. Ankylosing spondylitis. 2010; 3: 52–57.
45. Neznanov N. G., Bortsov A. V. A new quality of therapy for anxiety-depressive spectrum disorders – escitalopram. Journal of Neurology and Psychiatry. n. a. S. S. Korsakov. 2005; 2: 79–84.
46. Iznak A. F., Pozdeeva E. A., Iznak E. V. «Pure» stereoisomers – a new direction for increasing the effectiveness of antidepressants (literature review). Review of Psychiatry and Medical Psychology. Ankylosing spondylitis. 2008; 1.
47. Baumann P., Zullino D. F., Eap Ch. B. Enantiomer’s potential in psychopharmacology – a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacology. 2002; 12: 433–444.
48. Burke W. J., Gergel I., Bose A. Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients J Сlin Psychiat 2002; 63: 331–336.
49. Burke W. J., Kratochvil Ch. J. Stereoisomers in Psychiatry: The Case of Escitalopram. Primary Care Companion. J Clin Psychiatry. 2002; 4: 20–24.
50. Hogg S., Sбnchez C. The antidepressant effects of citalopram are mediated by the S-(+)- and not the R-(–)-enantiomer. Eur Neuropsychopharmacol 1999; 9 (Suppl 1): S 213.
51. Owens M. J., Knight D. L., Nemeroff C. B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiat. 2001; 50: 345–350.
52. von Moltke L. L., Greenblatt D. J., Giancarlo G. M. et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. 2001; 29: 1102–1109.
Review
For citations:
Medvedev V.E., Frolova V.I., Kotova O.V. Therapy of cardioneurosis with modern antidepressants in general medical care network. Medical alphabet. 2021;(25):26-32. (In Russ.) https://doi.org/10.33667/2078-5631-2021-25-26-32
Views:
734
Email this article 